Symbicort Study Finds Budesonide Component Key To Controlling Asthma
Executive Summary
A study of AstraZeneca's Symbicort (budesonide/ formoterol) as a reliever therapy for asthma exacerbations found that adding the inhaled corticosteroid budesonide results in additional reductions of severe exacerbations when compared to formoterol alone
You may also be interested in...
AstraZeneca Shelves Symbicort Launch Until 2007 To Prolong Product Life
AstraZeneca is delaying the launch of its asthma therapy Symbicort (budesonide/formoterol) until mid-2007 as it works to develop a longer shelf life for the product, the company said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials